低剂量白细胞介素-2在免疫相关性皮肤病中的研究进展  

Advances in the Role of Low-Dose Interleukin-2 in Immune-Mediated Dermatosis

作　　者：乔祖莎[1] 晋红中 QIAO Zusha;JIN Hongzhong(Department of Dermatology,Second Hospital of Shanxi Medical University,Taiyuan 030001,China;Department of Dermatology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China)

机构地区：[1]山西医科大学第二医院皮肤科,太原030001 [2]中国医学科学院、北京协和医学院、北京协和医院皮肤科,北京100730

出　　处：《中国医学科学院学报》2023年第4期683-688,共6页Acta Academiae Medicinae Sinicae

基　　金：山西省应用基础研究青年项目(20210302124693)。

摘　　要：免疫相关性皮肤病是一类因自身免疫耐受破坏导致的皮肤病,包括红斑狼疮、皮肌炎等。调节性T细胞与效应性T细胞之间失衡在免疫相关性皮肤病发病机制中起重要作用。低剂量白细胞介素-2可优先激活调节性T细胞,逆转调节性T细胞与效应性T细胞失衡,恢复免疫耐受,在免疫相关性皮肤病的治疗领域中逐渐受到关注。本文综述了低剂量白细胞介素-2的免疫调控机制及临床研究进展,为免疫相关性皮肤病的治疗提供新的思路。Immune-mediated dermatoses are the skin diseases caused by the breakdown of immune tolerance,including lupus erythematosus and dermatomyositis.The imbalance between regulatory T cells(Tregs)and effector T cells(Teffs)plays a key role in the pathogenesis of these diseases.Low-dose interleukin-2 can preferentially activate Tregs and reverse the imbalance between Tregs and Teffs to recover the immune tolerance,which has attracted attention in the treatment of immune-mediated dermatoses.This review summarizes the research progress in the immunomodulatory mechanism and clinical application of low-dose interleukin-2 in immune-mediated dermatoses,providing a new idea for the clinical treatment of these diseases.

关 键 词：白细胞介素-2 调节性T细胞 免疫相关性皮肤病 效应T细胞 

分 类 号：R75[医药卫生—皮肤病学与性病学]